GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Equity-to-Asset

Reunion Neuroscience (TSX:REUN) Equity-to-Asset : 0.72 (As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Reunion Neuroscience's Total Stockholders Equity for the quarter that ended in Mar. 2023 was C$21.30 Mil. Reunion Neuroscience's Total Assets for the quarter that ended in Mar. 2023 was C$29.74 Mil.

The historical rank and industry rank for Reunion Neuroscience's Equity-to-Asset or its related term are showing as below:

TSX:REUN's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

Reunion Neuroscience Equity-to-Asset Historical Data

The historical data trend for Reunion Neuroscience's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Equity-to-Asset Chart

Reunion Neuroscience Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
0.83 0.90 0.66 0.72

Reunion Neuroscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.61 0.88 0.73 0.72

Competitive Comparison of Reunion Neuroscience's Equity-to-Asset

For the Biotechnology subindustry, Reunion Neuroscience's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reunion Neuroscience's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reunion Neuroscience's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Reunion Neuroscience's Equity-to-Asset falls into.



Reunion Neuroscience Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Reunion Neuroscience's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=21.295/29.74
=

Reunion Neuroscience's Equity to Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

Equity to Asset (Q: Mar. 2023 )=Total Stockholders Equity/Total Assets
=21.295/29.74
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reunion Neuroscience  (TSX:REUN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Reunion Neuroscience Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Reunion Neuroscience (TSX:REUN) Business Description

Traded in Other Exchanges
N/A
Address
30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3
Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.